Recent Updates
Recently added Catalysts

Piperacillin

Phase 3

Hematologic Neoplasms | Small molecule | Oncology |Pfizer, Inc.|Last Updated: Oct 10, 2007

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment -

FDA Designations

No designations recorded

Clinical trial landscape

Piperacillin · 1 trial · 1 indication

Phase 3 1
NCT00044759Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or LymphomaHematologic Neoplasms
COMPLETED- Analytics
PHASE3COMPLETED
Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma
Hematologic Neoplasms
NCT00044759-
Unlock trial analytics

Study Design & Arms

PurposeTREATMENT

Interventions

NameTypeDescription
Piperacillin/Tazobactam (Tazocin)DRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites36

Inclusion Criteria: * Hospitalized male and female patients, 18 years of age or older * Patients who have leukemia (acute lymphocytic leukemia \[ALL\], acute myelogenous leukemia \[AML\], chronic lymphocytic leukemia \[CLL\], chronic myelogenous leukemia \[CML\]), that is newly diagnosed, who have ...

Countries:United StatesCanada
Unlock Eligibility Criteria